1 Laboratory of Immunity and Infection, UPMC Univ Paris 06, UMR-S945, Paris, France.
Am J Respir Crit Care Med. 2014 May 15;189(10):1240-9. doi: 10.1164/rccm.201311-2071OC.
The biology of fatal pandemic influenza infection remains undefined.
To characterize the virologic and immune parameters associated with severity or death in patients who required mechanical ventilation for A(H1N1) 2009 pneumonia of various degrees of severity during the two waves of the 2009-2011 pandemic in Paris, France.
This multicenter study included 34 unvaccinated patients with very severe or fatal confirmed influenza A(H1N1) infections. It analyzed plasma A(H1N1) 2009 reverse-transcriptase polymerase chain reaction, hemagglutinin 222G viral mutation, and humoral and cellular immune responses to the virus, assessed in hemagglutination inhibition (HI), microneutralization, ELISA, lymphoproliferative, ELISpot IFN-γ, and cytokine and chemokine assays.
The patients' median age was 35 years. Influenza A(H1N1) 2009 viremia was detected in 4 of 34 cases, and a 222G hemagglutinin mutation in 7 of 17 cases, all of them with sequential organ failure assessment greater than or equal to 8. HI antibodies were detectable in 19 of 26 survivors and undetectable in all six fatal fulminant cases. ELISA and microneutralization titers were concordant. B-cell immunophenotyping and plasma levels of immunoglobulin classes did not differ between patients who survived and died. After immune complex dissociation, influenza ELISA serology became strongly positive in the bronchoalveolar lavage of the two fatal cases tested. H1N1-specific T-cell responses in lymphoproliferative and IFN-γ assays were detectable in survivors' peripheral blood, and lymphoproliferative assays were negative in the three fatal cases tested. Plasma levels of IL-6 and IL-10 were high in fatal cases and correlated with severity. Finally, a negative HI serology 4 days after the onset of influenza symptoms predicted death from fulminant influenza (P = 0.04).
Early negative A(H1N1) 2009 HI serology can predict death from influenza. This negative serology in fatal cases in young adults reflects the trapping of anti-H1N1 antibodies in immune complexes in the lungs, associated with poor specific helper T-cell response. Clinical trial registered with www.clinicaltrials.gov (NCT 01089400).
致命大流行性流感感染的生物学特性仍未确定。
在法国巴黎的 2009-2011 年大流行的两波疫情中,对因严重程度不同而需要机械通气的 A(H1N1)2009 肺炎患者,分析与严重程度或死亡相关的病毒学和免疫参数。
这项多中心研究纳入了 34 例未接种疫苗的严重或致命确诊 A(H1N1)感染患者。分析了血浆 A(H1N1)2009 逆转录酶聚合酶链反应、血凝素 222G 病毒突变以及针对病毒的体液和细胞免疫反应,通过血凝抑制(HI)、微量中和、ELISA、淋巴细胞增殖、ELISpot IFN-γ以及细胞因子和趋化因子检测进行评估。
患者中位年龄为 35 岁。在 34 例患者中,4 例检测到流感 A(H1N1)2009 病毒血症,17 例中有 7 例检测到 222G 血凝素突变,所有患者的序贯器官衰竭评估(SOFA)均大于或等于 8。在 26 例幸存者中有 19 例可检测到 HI 抗体,而在所有 6 例致命性暴发性病例中均无法检测到 HI 抗体。ELISA 和微量中和滴度一致。存活组和死亡组患者的 B 细胞免疫表型和免疫球蛋白类血浆水平无差异。在经免疫复合物解离后,在检测的 2 例致命病例的支气管肺泡灌洗液中,流感 ELISA 血清学检测结果呈强阳性。在幸存者的外周血中可检测到 H1N1 特异性 T 细胞反应,而在检测的 3 例致命病例的淋巴细胞增殖试验中呈阴性。在致命病例中,IL-6 和 IL-10 血浆水平较高,与严重程度相关。最后,流感症状发作后 4 天 HI 血清学检测呈阴性,可预测暴发性流感死亡(P = 0.04)。
早期流感 A(H1N1)2009 HI 血清学检测阴性可预测流感死亡。在年轻成年人的致命病例中,这种阴性血清学检测反映了抗 H1N1 抗体在肺部免疫复合物中的截留,与辅助性 T 细胞特异性反应不良有关。本临床试验已在 www.clinicaltrials.gov 注册(NCT 01089400)。